Indications for DOPTELET:
Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Start treatment 10–13 days prior to a procedure. Should undergo procedure within 5–8 days after last dose. Take with food. Platelet count (<40 x 109/L): 60mg once daily for 5 days; (40–<50 x 109/L): 40mg once daily for 5 days.
Obtain platelet count prior to treatment and on day of procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Do not use to normalize platelet counts. Pregnancy; may cause fetal harm. Nursing mothers: not recommended (during and for ≥2 weeks after last dose).
Thrombopoietin receptor agonist.
Pyrexia, abdominal pain, nausea, headache, fatigue, peripheral edema; thrombotic/thromboembolic complications.